The latest news on the official launch of pirtobrutinib on August 16

On August 16, 2024, Pirtobrutinib (Pirtobrutinib) was officially announced to be launched in the United States. This news has attracted widespread attention in the field of hematological tumor treatment. As a new generation of non-covalent Bruton's tyrosine kinase (BTK) inhibitor, pitobrutinib is considered to have significant efficacy in a variety of relapsed or refractory B cell malignant tumors due to its innovative mechanism. This launch marks the drug’s official entry into the commercialization stage, providing new treatment hope for more patients around the world.

The mechanism of Pitobrutinib is to selectively and reversibly target the BTK protein, effectively bypassing the resistance mutations produced by traditional covalent BTK inhibitors (such as ibrutinib). It is especially suitable for patients carrying the C481 mutation. Relevant clinical data shows that the drug has shown a high response rate and duration in hematological tumors such as mantle cell lymphoma (MCL), chronic lymphocytic leukemia (CLL), and is especially effective for patients who have received multiple treatments in the past but with poor results.

Although pitobrutinib has entered clinical use overseas, it has not yet been officially approved for marketing in mainland China. Domestic patients are temporarily unable to purchase this medicine directly through regular hospitals or pharmacies, and must rely on cross-border medical treatment, overseas purchasing and other channels to obtain the medicine. There is a big difference in price: the original research version (50mg*30 tablets) in the US market sells for about 100,000 yuan per person RMB, which is a heavy burden for most patients; in contrast, the generic version launched by Lao pharmaceutical companies has significantly lowered the threshold for medication, with each box only costing RMB 2,000, making it an economical alternative.

Overall, the launch of pitobrutinib undoubtedly provides a new treatment breakthrough for patients with hematological tumors. If it can enter the Chinese market and be included in the medical insurance system as soon as possible in the future, it will greatly improve patient accessibility and compliance. If domestic patients currently need medicines, it is recommended that they obtain information about overseas versions of medicines under the guidance of professional doctors to ensure safe and rational use of medicines, and at the same time pay close attention to domestic approval progress and clinical trial trends.

Reference materials:https://www.drugs.com/